Health care pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 health care pharmaceutical companies ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8). Figures as of 19 Nov 2026, 22:37 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 39.3
- Combined market value
- PLN 20.05T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | PLN 18.2B | PLN 166.38 | 0.48% down | 86% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | PLN 80B | PLN 597.37 | 1.06% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 9.8 | PLN 692.3B | PLN 157.08 | 1.42% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 9.9 | PLN 22.6B | PLN 33.14 | 3.19% down | 0% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 12.9 | PLN 481.9B | PLN 235.76 | 2.05% down | 30% up | ||
| 6 | ZoetisZTS · Health Care | 13.7 | PLN 132.7B | PLN 326.49 | 5.59% down | 26% down | ||
| 7 | GSKGSK · Health Care | 16.7 | PLN 387.4B | PLN 193.25 | 1.56% down | 5% up | ||
| 8 | Ascendis PharmaASND · Health Care | 16.8 | PLN 67.9B | PLN 1,034.39 | 5.32% down | 29% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 20.4 | PLN 386B | PLN 3,731.41 | 2.35% down | 28% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.1 | PLN 96.2B | PLN 2,259.44 | 3.16% down | 22% up | ||
| 11 | SanofiSNY · Health Care | 22.9 | PLN 447B | PLN 186.14 | 2.25% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 24.8 | PLN 1.1T | PLN 708.87 | 1.87% down | 1% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.2 | PLN 32.7B | PLN 501.19 | 2.47% down | 51% up | ||
| 14 | NovartisNVS · Health Care | 28.9 | PLN 1.15T | PLN 611.11 | 2.57% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 33.5 | PLN 533.5B | PLN 2,104.10 | 2.94% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.8 | PLN 727B | PLN 419.76 | 0.58% down | 16% down | ||
| 17 | PfizerPFE · Health Care | 39.3 | PLN 634.4B | PLN 111.29 | 1.85% down | 15% up | ||
| 18 | Johnson & JohnsonJNJ · Health Care | 40.5 | PLN 2.6T | PLN 1,079.57 | 2.04% down | 34% up | ||
| 19 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.2 | PLN 50B | PLN 59.93 | 1.00% down | 8% up | ||
| 20 | Eli LillyLLY · Health Care | 43.9 | PLN 4.86T | PLN 5,460.16 | 2.29% down | 33% up | ||
| 21 | GenmabGMAB · Health Care | 43.9 | PLN 128B | PLN 207.52 | 0.75% up | 70% up | ||
| 22 | Royalty PharmaRPRX · Health Care | 44.3 | PLN 157.4B | PLN 273.67 | 1.38% down | 79% up | ||
| 23 | AbbVieABBV · Health Care | 48.7 | PLN 2.03T | PLN 1,145.84 | 0.86% down | 25% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 48.9 | PLN 28.7B | PLN 262.60 | 4.15% down | 10% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.2 | PLN 184.5B | PLN 1,615.27 | 0.97% down | 16% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.5 | PLN 30.1B | PLN 86.44 | 2.24% down | 90% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 70.0 | PLN 61.3B | PLN 955.54 | 4.57% down | 41% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 70.9 | PLN 29.7B | PLN 377.99 | 1.59% down | 129% up | ||
| 29 | Teva Pharmaceutical IndustriesTEVA · Health Care | 89.6 | PLN 181.7B | PLN 155.75 | 8.74% down | 74% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | 96.8 | PLN 39.6B | PLN 262.19 | 1.88% down | 117% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 115 | PLN 23.2B | PLN 1,159.58 | 3.94% down | 50% up | ||
| 32 | Merck & CoMRK · Health Care | 134 | PLN 1.32T | PLN 536.71 | 3.61% down | 45% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 306 | PLN 276.4B | PLN 86.52 | 0.66% up | 51% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0412 PLN). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8) have the lowest P/E ratio of the 33 health care pharmaceutical companies ranked here as of 19 Nov 2026, 22:37 UTC.
How many health care pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 33 health care pharmaceutical companies ranked by P/E ratio have a combined market value of PLN 20.05T as of 19 Nov 2026, 22:37 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care pharmaceutical companies by P/E ratio”, data as of 19 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.